{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:58:56Z","timestamp":1790348336333,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"DOI":"10.1186\/s40959-026-00536-5","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T23:24:13Z","timestamp":1783121053000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular event burden in women with breast cancer treated with CDK4\/6 inhibitors: a retrospective matched cohort study"],"prefix":"10.1186","volume":"12","author":[{"given":"Veerle","family":"Leenaerts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Cauwenberghs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Wildiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Neven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Kuznetsova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Van Aelst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"key":"536_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081758","volume":"13","author":"E Raschi","year":"2021","unstructured":"Raschi E, Fusaroli M, Ardizzoni A, Poluzzi E, De Ponti F. Thromboembolic events with cyclin-dependent kinase 4\/6 inhibitors in the FDA adverse event reporting system. Cancers (Basel). 2021;13:1758. https:\/\/doi.org\/10.3390\/cancers13081758.","journal-title":"Cancers (Basel)"},{"key":"536_CR2","doi-asserted-by":"publisher","unstructured":"Liu YS, Dong K, Park C. Risk of cardiovascular events with cyclin-dependent kinases 4 and 6 inhibitors among patients with advanced breast cancer: a systematic review and network meta-analysis. Rev Cardiovasc Med. 2023;24:309. https:\/\/doi.org\/10.31083\/j.rcm2411309.","DOI":"10.31083\/j.rcm2411309"},{"key":"536_CR3","doi-asserted-by":"publisher","first-page":"175883592312058","DOI":"10.1177\/17588359231205848","volume":"15","author":"D Pavlovic","year":"2023","unstructured":"Pavlovic D, Niciforovic D, Papic D, Milojevic K, Markovic M. CDK4\/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity\u2014a narrative review. Ther Adv Med Oncol. 2023;15:17588359231205848. https:\/\/doi.org\/10.1177\/17588359231205848.","journal-title":"Ther Adv Med Oncol"},{"key":"536_CR4","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/ejh.13590","volume":"106","author":"MT West","year":"2021","unstructured":"West MT, Smith CE, Kaempf A, et al. CDK4\/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice. Eur J Haematol. 2021;106:634\u201342. https:\/\/doi.org\/10.1111\/ejh.13590.","journal-title":"Eur J Haematol"},{"key":"536_CR5","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc1495","volume":"375","author":"A Fassl","year":"2022","unstructured":"Fassl A, Geng Y, Sicinski P. CDK4 and CDK6 kinases: from basic science to cancer therapy. Science. 2022;375:eabc1495. https:\/\/doi.org\/10.1126\/science.abc1495.","journal-title":"Science"},{"key":"536_CR6","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.029361","volume":"12","author":"MG Fradley","year":"2023","unstructured":"Fradley MG, Nguyen NHK, Madnick D, et al. Adverse cardiovascular events associated with cyclin-dependent kinase 4\/6 inhibitors in patients with metastatic breast cancer. J Am Heart Assoc. 2023;12:e029361. https:\/\/doi.org\/10.1161\/JAHA.123.029361.","journal-title":"J Am Heart Assoc"},{"issue":"16 Suppl","key":"536_CR7","doi-asserted-by":"publisher","first-page":"e15074","DOI":"10.1200\/JCO.2023.41.16_suppl.e15074","volume":"41","author":"O Fiste","year":"2023","unstructured":"Fiste O, Liontos M, Gavriatopoulou M, et al. CDK4\/6 inhibitors and cardiovascular toxicity: real-world evidence. J Clin Oncol. 2023;41(16 Suppl):e15074. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e15074.","journal-title":"J Clin Oncol"},{"key":"536_CR8","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s40259-019-00382-1","volume":"33","author":"M Santoni","year":"2019","unstructured":"Santoni M, Occhipinti G, Romagnoli E, et al. Different cardiotoxicity of palbociclib and ribociclib in breast cancer: gene expression and pharmacological data analyses, biological basis, and therapeutic implications. BioDrugs. 2019;33:613\u201320. https:\/\/doi.org\/10.1007\/s40259-019-00382-1.","journal-title":"BioDrugs"},{"key":"536_CR9","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.3390\/cancers16162869","volume":"16","author":"JH Kim","year":"2024","unstructured":"Kim JH. Profiling the cardiovascular toxicities of CDK4\/6 inhibitors: a real-world pharmacovigilance study. Cancers (Basel). 2024;16:2869. https:\/\/doi.org\/10.3390\/cancers16162869.","journal-title":"Cancers (Basel)"},{"key":"536_CR10","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.hemonc.2020.03.001","volume":"14","author":"S Ball","year":"2021","unstructured":"Ball S, Swarup S, Sultan A, Thein KZ. Increased risk of cardiac conduction abnormalities with ribociclib in patients with metastatic breast cancer: a combined analysis of phase III randomized controlled trials. Hematol Oncol Stem Cell Ther. 2021;14:260\u20132. https:\/\/doi.org\/10.1016\/j.hemonc.2020.03.001.","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"536_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104296","volume":"196","author":"O Fiste","year":"2024","unstructured":"Fiste O, Mavrothalassitis E, Apostolidou K, et al. Cardiovascular complications of ribociclib in breast cancer patients. Crit Rev Oncol Hematol. 2024;196:104296. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104296.","journal-title":"Crit Rev Oncol Hematol"},{"key":"536_CR12","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jtha.2022.12.001","volume":"21","author":"NW Watson","year":"2023","unstructured":"Watson NW, Shatzel JJ, Al-Samkari H. Cyclin-dependent kinase 4\/6 inhibitor-associated thromboembolism: a critical evaluation of the current evidence. J Thromb Haemost. 2023;21:758\u201370. https:\/\/doi.org\/10.1016\/j.jtha.2022.12.001.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"536_CR13","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10549-020-05783-3","volume":"183","author":"KZ Thein","year":"2020","unstructured":"Thein KZ, Htut TW, Ball S, Swarup S, Sultan A, Oo TH. Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4\/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials. Breast Cancer Res Treat. 2020;183(2):479\u201387. https:\/\/doi.org\/10.1007\/s10549-020-05783-3.","journal-title":"Breast Cancer Res Treat"},{"key":"536_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1001\/jamaoncol.2018.5529","volume":"5","author":"SR Olson","year":"2019","unstructured":"Olson SR, DeLoughery TG, Shatzel JJ. Cyclin-dependent kinase inhibitor-associated thromboembolism. JAMA Oncol. 2019;5:141\u20132. https:\/\/doi.org\/10.1001\/jamaoncol.2018.5529.","journal-title":"JAMA Oncol"},{"key":"536_CR15","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.thromres.2021.11.009","volume":"208","author":"E Bolzacchini","year":"2021","unstructured":"Bolzacchini E, Pomero F, Fazio M, et al. Risk of venous and arterial thromboembolic events in women with advanced breast cancer treated with CDK4\/6 inhibitors: a systematic review and meta-analysis. Thromb Res. 2021;208:190\u20137. https:\/\/doi.org\/10.1016\/j.thromres.2021.11.009.","journal-title":"Thromb Res"},{"key":"536_CR16","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1080\/14740338.2023.2181338","volume":"22","author":"S Gao","year":"2023","unstructured":"Gao S, Li Y, He Z, et al. Thromboembolism profiles associated with cyclin-dependent kinase 4\/6 inhibitors: a real-world pharmacovigilance study and a systematic review. Expert Opin Drug Saf. 2023;22:599\u2013609. https:\/\/doi.org\/10.1080\/14740338.2023.2181338.","journal-title":"Expert Opin Drug Saf"},{"key":"536_CR17","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/jth.14630","volume":"18","author":"L Gervaso","year":"2020","unstructured":"Gervaso L, Montero AJ, Jia X, Khorana AA. Venous thromboembolism in breast cancer patients receiving CDK inhibitors. J Thromb Haemost. 2020;18:162\u20138. https:\/\/doi.org\/10.1111\/jth.14630.","journal-title":"J Thromb Haemost"},{"issue":"Suppl 1","key":"536_CR18","doi-asserted-by":"publisher","first-page":"S354","DOI":"10.1016\/j.annonc.2024.08.273","volume":"35","author":"L Boismoreau","year":"2024","unstructured":"Boismoreau L, Dolladille C, Bastien E, et al. 334P Cardiovascular events related to CDK4\/6 inhibitors: a systematic review and safety meta-analysis of randomized controlled trials. Ann Oncol. 2024;35(Suppl 1):S354. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.273.","journal-title":"Ann Oncol"},{"key":"536_CR19","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1002\/ijc.35255","volume":"156","author":"T Li","year":"2025","unstructured":"Li T, Zhang M, Zhang T, et al. CDK4\/6 inhibitors and cardiotoxic events in breast cancer: FAERS pharmacovigilance study. Int J Cancer. 2025;156:1404\u201318. https:\/\/doi.org\/10.1002\/ijc.35255.","journal-title":"Int J Cancer"},{"issue":"Suppl 1","key":"536_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvae088.002","volume":"120","author":"A Linders","year":"2024","unstructured":"Linders A, Dias I, Meyer C, et al. CDK4\/6 inhibitor ribociclib induces cardiotoxicity in dynamic engineered heart tissues, mitigated by E2F1 overexpression. Cardiovasc Res. 2024;120(Suppl 1):cvae088.002. https:\/\/doi.org\/10.1093\/cvr\/cvae088.002.","journal-title":"Cardiovasc Res"},{"key":"536_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.638895","volume":"8","author":"C Papageorgiou","year":"2021","unstructured":"Papageorgiou C, Zagouri F, Tampakis K, et al. Vascular inflammation and cardiovascular burden in metastatic breast cancer receiving CDK4\/6 inhibitors. Front Cardiovasc Med. 2021;8:638895. https:\/\/doi.org\/10.3389\/fcvm.2021.638895.","journal-title":"Front Cardiovasc Med"},{"key":"536_CR22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S1470-2045(20)30757-9","volume":"22","author":"B Xu","year":"2021","unstructured":"Xu B, Fan Y. CDK4\/6 inhibition in early breast cancer: how far from standard of care? Lancet Oncol. 2021;22:159\u201360. https:\/\/doi.org\/10.1016\/S1470-2045(20)30757-9.","journal-title":"Lancet Oncol"},{"issue":"11","key":"536_CR23","doi-asserted-by":"publisher","first-page":"e690","DOI":"10.1016\/S2666-7568(21)00226-9","volume":"2","author":"DS Martens","year":"2021","unstructured":"Martens DS, Thijs L, Latosinska A, et al. Urinary peptidomic profiles to address age-related disabilities: a prospective population study. Lancet Healthy Longev. 2021;2(11):e690\u2013703. https:\/\/doi.org\/10.1016\/S2666-7568(21)00226-9.","journal-title":"Lancet Healthy Longev"},{"key":"536_CR24","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate. J R Stat Soc Series B. 1995;57:289\u2013300.","journal-title":"J R Stat Soc Series B"},{"key":"536_CR25","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141\u201354. https:\/\/doi.org\/10.1214\/aos\/1176350951.","journal-title":"Ann Stat"},{"key":"536_CR26","doi-asserted-by":"publisher","first-page":"275","DOI":"10.6004\/jnccn.2020.7629","volume":"19","author":"AA Matthews","year":"2021","unstructured":"Matthews AA, Peacock Hinton S, Stanway S, Lyon AR, Smeeth L, Bhaskaran K, et al. Risk of cardiovascular diseases among older breast cancer survivors in the United States: a matched cohort study. J Natl Compr Canc Netw. 2021;19:275\u201384. https:\/\/doi.org\/10.6004\/jnccn.2020.7629.","journal-title":"J Natl Compr Canc Netw"},{"key":"536_CR27","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jjcc.2018.10.009","volume":"73","author":"R Hamood","year":"2019","unstructured":"Hamood R, Hamood H, Merhasin I, Keinan-Boker L. Risk of cardiovascular disease after radiotherapy in survivors of breast cancer: a case-cohort study. J Cardiol. 2019;73:280\u201391. https:\/\/doi.org\/10.1016\/j.jjcc.2018.10.009.","journal-title":"J Cardiol"},{"key":"536_CR28","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1093\/eurjpc\/zwad243","volume":"30","author":"A Galimzhanov","year":"2023","unstructured":"Galimzhanov A, Istanbuly S, Tun HN, Ozbay B, Alasnag M, Ky B, et al. Cardiovascular outcomes in breast cancer survivors: a systematic review and meta-analysis. Eur J Prev Cardiol. 2023;30:2018\u201331. https:\/\/doi.org\/10.1093\/eurjpc\/zwad243.","journal-title":"Eur J Prev Cardiol"},{"key":"536_CR29","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ijrobp.2015.11.040","volume":"94","author":"NB Boekel","year":"2016","unstructured":"Boekel NB, Schaapveld M, Gietema JA, Russell NS, Poortmans P, Theuws JCM, et al. Cardiovascular disease risk in a large, population-based cohort of breast cancer survivors. Int J Radiat Oncol Biol Phys. 2016;94:1061\u201372. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.11.040.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"536_CR30","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1002\/cncr.34367","volume":"128","author":"NW Watson","year":"2022","unstructured":"Watson NW, Wander SA, Shatzel JJ, Al-Samkari H. Venous and arterial thrombosis associated with abemaciclib therapy for metastatic breast cancer. Cancer. 2022;128:3224\u201332. https:\/\/doi.org\/10.1002\/cncr.34367.","journal-title":"Cancer"},{"key":"536_CR31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.11838","volume":"2","author":"H Abdel-Qadir","year":"2019","unstructured":"Abdel-Qadir H, Thavendiranathan P, Fung K, Amir E, Austin PC, Anderson GS, et al. Association of early-stage breast cancer and subsequent chemotherapy with risk of atrial fibrillation. JAMA Netw Open. 2019;2:e1911838. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.11838.","journal-title":"JAMA Netw Open"},{"key":"536_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2026.134466","volume":"454","author":"NE Davis","year":"2026","unstructured":"Davis NE, Herrmann J, Hodge DO, Blumenfeld S, Ruddy KJ, Tan NY. Incidence and outcomes of atrial arrhythmia with cyclin-dependent kinase 4\/6 inhibitors in hormone receptor-positive, HER2-negative breast cancer. Int J Cardiol. 2026;454:134466. https:\/\/doi.org\/10.1016\/j.ijcard.2026.134466.","journal-title":"Int J Cardiol"},{"key":"536_CR33","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/CAD.0000000000000589","volume":"29","author":"C Durairaj","year":"2018","unstructured":"Durairaj C, Ruiz-Garcia A, Gauthier ER, Huang X, Lu DR, Hoffman JT, et al. Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer. Anticancer Drugs. 2018;29:271\u201380. https:\/\/doi.org\/10.1097\/CAD.0000000000000589.","journal-title":"Anticancer Drugs"},{"key":"536_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkae078","volume":"8","author":"B Murad","year":"2024","unstructured":"Murad B, Reis PCA, Deberaldini Marinho A, Marin Comini AC, Pinheiro Xavier D, Mella Soares Pessoa B, et al. QTc prolongation across CDK4\/6 inhibitors: a systematic review and meta-analysis of randomized controlled trials. JNCI Cancer Spectr. 2024;8:pkae078. https:\/\/doi.org\/10.1093\/jncics\/pkae078.","journal-title":"JNCI Cancer Spectr"},{"key":"536_CR35","doi-asserted-by":"publisher","first-page":"R64","DOI":"10.1186\/bcr2901","volume":"13","author":"JL Patnaik","year":"2011","unstructured":"Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res. 2011;13:R64. https:\/\/doi.org\/10.1186\/bcr2901.","journal-title":"Breast Cancer Res"},{"key":"536_CR36","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43:4229\u2013361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244.","journal-title":"Eur Heart J"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-026-00536-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00536-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00536-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:03:07Z","timestamp":1790344987000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40959-026-00536-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["536"],"URL":"https:\/\/doi.org\/10.1186\/s40959-026-00536-5","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"29 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This single-centre retrospective matched cohort study was approved by the Ethics Committee UZ\/KU Leuven (approval numbers s68763 and s64406). The need for individual patient consent was waived by the ethics committee due to the retrospective nature of the study and use of anonymised data.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript does not contain identifiable individual participant data.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"118"}}